1. Key Insights 2. Sialorrhea Market Overview at a Glance 2.1. Market Share (%) of Sialorrhea in 2017 – 7MM 2.2. Market Share (%) of Sialorrhea in 2028 – 7MM 3. Disease Background and Overview 3.1. Introduction 3.2. Classification of Sialorrhea 3.3. Etiology of Sialorrhea 3.4. Sialorrhea associated risk factors 3.5. Physiology of salivary function 3.6. Pathophysiology of Sialorrhea 3.7. Clinical Features and Possible Complications of Sialorrhea 3.8. Assessment of Sialorrhea 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Cases of Sialorrhea in 7MM 5. Country Wise-Epidemiology 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States 5.1.3. Occurrence of Sialorrhea in the United States 5.1.4. Occurrence of Chronic Sialorrhea in the United States 5.2. EU-5 5.2.1. Assumptions and Rationale 5.2.2. Germany 5.2.3. France 5.2.4. Italy 5.2.5. Spain 5.2.6. United Kingdom 5.3. Japan 5.3.1. Assumptions and Rationale 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan 5.3.3. Occurrence of Sialorrhea in Japan 5.3.4. Occurrence of Chronic Sialorrhea in Japan 6. Treatment and Management 6.1. Treatment for Children 6.2. Treatment for Clozapine-induced Sialorrhea 6.3. Treatment of Sialorrhea in Parkinson’s disease 6.4. Patient Journey 7. Unmet Needs 8. Case Studies 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution 9. Marketed Products 9.1. Cuvposa: Merz Pharmaceuticals 9.1.1. Product Description 9.1.2. Product Development Activities 9.1.3. Clinical Development 9.1.4. Safety and Efficacy 9.1.5. Product Profile 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd 9.2.1. Product Description 9.2.2. Product Development Activities 9.2.3. Clinical Development 9.2.4. Product Profile 10. Emerging Drugs 10.1. Key Cross Competition 10.2. Myobloc: US WorldMeds 10.2.1. Product Description 10.2.2. Product Development Activities 10.2.3. Clinical Development 10.2.4. Safety and Efficacy 10.2.5. Product Profile 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma 10.3.1. Product Description 10.3.2. Product Development Activities 10.3.3. Clinical Development 10.3.4. Safety and Efficacy 10.3.5. Product Profile 10.4. NH004: NeuroHealing Pharmaceuticals 10.4.1. Product Description 10.4.2. Product Development Activities 10.4.3. Clinical Development 10.4.4. Safety and Efficacy 10.4.5. Product Profile 11. Other Clinical Candidates 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma 11.1.1. Product Description 11.1.2. Clinical Development 11.1.3. Product Profile 11.2. NT0502: Neos Therapeutics 11.2.1. Product Description 11.2.2. Product Development Activities 11.2.3. Product Profile 12. Off label Drugs 13. Sialorrhea: 7 Major Market Analysis 13.1. Key Findings 13.2. Market Size of Sialorrhea in 7MM 13.3. Market Outlook: 7MM 14. The United States Market Outlook 14.1. United States Market Size 14.1.1. Total Market size of Sialorrhea 14.1.2. Market Size by Therapies 15. EU-5 Countries: Market Outlook 15.1. Germany 15.1.1. Total Market size of Sialorrhea in Germany 15.1.2. Market Size by Therapies 15.2. France 15.2.1. Total Market Size of Sialorrhea 15.2.2. Market Size by Therapies 15.3. Italy 15.3.1. Total Market Size of Sialorrhea 15.3.2. Market Size by Therapies 15.4. Spain 15.4.1. Total Market Size of Sialorrhea 15.4.2. Market Size by Therapies 15.5. The United Kingdom 15.5.1. Total Market Size of Sialorrhea 15.5.2. Market Size by Therapies 16. Japan: Market Outlook 16.1. Japan Market Size 16.2. Total Market Size of Sialorrhea 16.3. Market Size by Therapies 17. Market Drivers 18. Market Barriers 19. Appendix 19.1. Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight 1. Key Insights 2. Sialorrhea Market Overview at a Glance 2.1. Market Share (%) of Sialorrhea in 2017 – 7MM 2.2. Market Share (%) of Sialorrhea in 2028 – 7MM 3. Disease Background and Overview 3.1. Introduction 3.2. Classification of Sialorrhea 3.3. Etiology of Sialorrhea 3.4. Sialorrhea associated risk factors 3.5. Physiology of salivary function 3.6. Pathophysiology of Sialorrhea 3.7. Clinical Features and Possible Complications of Sialorrhea 3.8. Assessment of Sialorrhea 4. Epidemiology and Patient Population 4.1. Key Findings 4.2. Total Cases of Sialorrhea in 7MM 5. Country Wise-Epidemiology 5.1. United States 5.1.1. Assumptions and Rationale 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States 5.1.3. Occurrence of Sialorrhea in the United States 5.1.4. Occurrence of Chronic Sialorrhea in the United States 5.2. EU-5 5.2.1. Assumptions and Rationale 5.2.2. Germany 5.2.3. France 5.2.4. Italy 5.2.5. Spain 5.2.6. United Kingdom 5.3. Japan 5.3.1. Assumptions and Rationale 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan 5.3.3. Occurrence of Sialorrhea in Japan 5.3.4. Occurrence of Chronic Sialorrhea in Japan 6. Treatment and Management 6.1. Treatment for Children 6.2. Treatment for Clozapine-induced Sialorrhea 6.3. Treatment of Sialorrhea in Parkinson’s disease 6.4. Patient Journey 7. Unmet Needs 8. Case Studies 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution 9. Marketed Products 9.1. Cuvposa: Merz Pharmaceuticals 9.1.1. Product Description 9.1.2. Product Development Activities 9.1.3. Clinical Development 9.1.4. Safety and Efficacy 9.1.5. Product Profile 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd 9.2.1. Product Description 9.2.2. Product Development Activities 9.2.3. Clinical Development 9.2.4. Product Profile 10. Emerging Drugs 10.1. Key Cross Competition 10.2. Myobloc: US WorldMeds 10.2.1. Product Description 10.2.2. Product Development Activities 10.2.3. Clinical Development 10.2.4. Safety and Efficacy 10.2.5. Product Profile 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma 10.3.1. Product Description 10.3.2. Product Development Activities 10.3.3. Clinical Development 10.3.4. Safety and Efficacy 10.3.5. Product Profile 10.4. NH004: NeuroHealing Pharmaceuticals 10.4.1. Product Description 10.4.2. Product Development Activities 10.4.3. Clinical Development 10.4.4. Safety and Efficacy 10.4.5. Product Profile 11. Other Clinical Candidates 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma 11.1.1. Product Description 11.1.2. Clinical Development 11.1.3. Product Profile 11.2. NT0502: Neos Therapeutics 11.2.1. Product Description 11.2.2. Product Development Activities 11.2.3. Product Profile 12. Off label Drugs 13. Sialorrhea: 7 Major Market Analysis 13.1. Key Findings 13.2. Market Size of Sialorrhea in 7MM 13.3. Market Outlook: 7MM 14. The United States Market Outlook 14.1. United States Market Size 14.1.1. Total Market size of Sialorrhea 14.1.2. Market Size by Therapies 15. EU-5 Countries: Market Outlook 15.1. Germany 15.1.1. Total Market size of Sialorrhea in Germany 15.1.2. Market Size by Therapies 15.2. France 15.2.1. Total Market Size of Sialorrhea 15.2.2. Market Size by Therapies 15.3. Italy 15.3.1. Total Market Size of Sialorrhea 15.3.2. Market Size by Therapies 15.4. Spain 15.4.1. Total Market Size of Sialorrhea 15.4.2. Market Size by Therapies 15.5. The United Kingdom 15.5.1. Total Market Size of Sialorrhea 15.5.2. Market Size by Therapies 16. Japan: Market Outlook 16.1. Japan Market Size 16.2. Total Market Size of Sialorrhea 16.3. Market Size by Therapies 17. Market Drivers 18. Market Barriers 19. Appendix 19.1. Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight

Table 1: Objective methods to measure Sialorrhea Table 2: Objective methods to measure Sialorrhea Table 3: Total Population of Sialorrhea in 7MM (2017-2028) Table 4: Epidemiology of Sialorrhea Associated Etiologies in the United States (2017-2028) Table 5: Occurrence of Sialorrhea in the United States (2017-2028) Table 6: Occurrence of Chronic Sialorrhea in the United States (2017-2028) Table 7: Epidemiology of Sialorrhea Associated Etiologies in Germany (2017-2028) Table 8: Occurrence of Sialorrhea in Germany (2017-2028) Table 9: Occurrence of Chronic Sialorrhea in Germany (2017-2028) Table 10: Epidemiology of Sialorrhea Associated Etiologies in France (2017-2028) Table 11: Occurrence of Sialorrhea in France (2017-2028) Table 12: Occurrence of Chronic Sialorrhea in France (2017-2028) Table 13: Epidemiology of Sialorrhea Associated Etiologies in Italy (2017-2028) Table 14: Occurrence of Sialorrhea in Italy (2017-2028) Table 15: Occurrence of Chronic Sialorrhea in Italy (2017-2028) Table 16: Epidemiology of Sialorrhea Associated Etiologies in Spain (2017-2028) Table 17: Occurrence of Sialorrhea in Spain (2017-2028) Table 18: Occurrence of Chronic Sialorrhea in Spain (2017-2028) Table 19: Epidemiology of Sialorrhea Associated Etiologies in the United Kingdom (2017-2028) Table 20: Occurrence of Sialorrhea in the United Kingdom (2017-2028) Table 21: Occurrence of Chronic Sialorrhea in the United Kingdom (2017-2028) Table 22: Epidemiology of Sialorrhea Associated Etiologies in Japan (2017-2028) Table 23: Occurrence of Sialorrhea in Japan (2017-2028) Table 24: Occurrence of Chronic Sialorrhea in Japan (2017-2028) Table 25: Surgical treatment of drooling⁄sialorrhea Table 26: Xeomin, Clinical Trial Description, 2019 Table 27: NH004, Clinical Trial Description, 2019 Table 28: OP-014, Clinical Trial Description, 2019 Table 29: Comparison of different off label anti-cholinergic medications Table 30: Suggested dosages for the management of drooling with botulinum toxin Table 31: 7 Major Market Size of Sialorrhea in USD Million (2017-2028) Table 32: United States Market Size of Sialorrhea in the US, USD Million (2017-2028) Table 33: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028) Table 34: Germany Market Size of Sialorrhea in Germany, USD Million (2017-2028) Table 35: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028) Table 36: France Market Size of Sialorrhea in France, USD Million (2017-2028) Table 37: Market Size of Sialorrhea by Therapies in France, in USD Million (2017-2028) Table 38: Italy Market Size of Sialorrhea in Italy, USD Million (2017-2028) Table 39: Market Size of Sialorrhea by Therapies in Italy, in USD Million (2017-2028) Table 40: Spain Market Size of Sialorrhea in Spain, USD Million (2017-2028) Table 41: Market Size of Sialorrhea by Therapies in Spain, in USD Million (2017-2028) Table 42: UK Market Size of Sialorrhea in UK, USD Million (2017-2028) Table 43: Market Size of Sialorrhea by Therapies in UK, in USD Million (2017-2028) Table 44: Japan Market Size of Sialorrhea in Japan, USD Million (2017-2028) Table 45: Market Size of Sialorrhea by Therapies in Japan, in USD Million (2017-2028) Figure 1: Etiology of Sialorrhea Figure 2: Etiology of Sialorrhea Figure 3: Reflex secretion of saliva from major salivary glands Figure 4: Possible pathophysiology of drooling in Parkinson's disease Figure 5:Interaction between the clinical aspects involved in the health of children with CP Figure 6: Total Population of Sialorrhea in 7 MM (2017-2028) Figure 7: Epidemiology of Sialorrhea Associated Etiologies in the United States (2017-2028) Figure 8: Occurrence of Sialorrhea in the United States (2017-2028) Figure 9: Occurrence of Chronic Sialorrhea in the United States (2017-2028) Figure 10: Epidemiology of Sialorrhea Associated Etiologies in Germany (2017-2028) Figure 11: Occurrence of Sialorrhea in Germany (2017-2028) Figure 12: Prevalence of Chronic Sialorrhea in Germany (2017-2028) Figure 13: Epidemiology of Sialorrhea Associated Etiologies in France (2017-2028) Figure 14: Occurrence of Sialorrhea in France (2017-2028) Figure 15: Occurrence of Chronic Sialorrhea in France (2017-2028) Figure 16: Epidemiology of Sialorrhea Associated Etiologies in Italy (2017-2028) Figure 17: Occurrence of Sialorrhea in Italy (2017-2028) Figure 18: Occurrence of Chronic Sialorrhea in Italy (2017-2028) Figure 19: Epidemiology of Sialorrhea Associated Etiologies in Spain (2017-2028) Figure 20: Occurrence of Sialorrhea in Spain (2017-2028) Figure 21: Occurrence of Chronic Sialorrhea in Spain (2017-2028) Figure 22: Epidemiology of Sialorrhea Associated Etiologies in the United Kingdom (2017-2028) Figure 23: Occurrence of Sialorrhea in the United Kingdom (2017-2028) Figure 24: Occurrence of Chronic Sialorrhea in the United Kingdom (2017-2028) Figure 25: Epidemiology of Sialorrhea Associated Etiologies in Japan (2017-2028) Figure 26: Occurrence of Sialorrhea in Japan (2017-2028) Figure 27: Occurrence of Chronic Sialorrhea in Japan (2017-2028) Figure 28: Mechanism of action of BoNT along with that of normal cell Figure 29: Treatment algorithm for treating Sialorrhea Figure 30: Treatment algorithm for treating Sialorrhea in children Figure 31: Patient Journey for Sialorrhea Figure 32: Unmet Needs for Sialorrhea Figure 33: 7 Major Market Size of Sialorrhea in USD Million (2017-2028) Figure 34: Market Size of Sialorrhea in the United States, USD Millions (2017-2028) Figure 35: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028) Figure 36: Market Size of Sialorrhea in Germany, USD Millions (2017-2028) Figure 37: Market Size of Sialorrhea by Therapies in the US, in USD Million (2017-2028) Figure 38: Market Size of Sialorrhea in the France, USD Millions (2017-2028) Figure 39: Market Size of Sialorrhea by Therapies in France, in USD Million (2017-2028) Figure 40: Market Size of Sialorrhea in Italy, USD Millions (2017-2028) Figure 41: Market Size of Sialorrhea by Therapies in Italy, in USD Million (2017-2028) Figure 42: Market Size of Sialorrhea in the Spain, USD Millions (2017-2028) Figure 43: Market Size of Sialorrhea by Therapies in Spain, in USD Million (2017-2028) Figure 44: Market Size of Sialorrhea in the UK, USD Millions (2017-2028) Figure 45: Market Size of Sialorrhea by Therapies in UK, in USD Million (2017-2028) Figure 46: Market Size of Sialorrhea in Japan, USD Millions (2017-2028) Figure 47: Market Size of Sialorrhea by Therapies in Japan, in USD Million (2017-2028) Figure 48: Market Drivers for Sialorrhea Figure 49: Market Barriers for Sialorrhea

• Merz Pharmaceuticals • US WorldMeds • Merz Pharmaceuticals • NeuroHealing • Proveca Ltd.